Physician profile
James J Magee
NPI 1770521007
$1,181.94
in general payments reported to CMS, 2019-2025
21 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $62.67 · 2021: $63.03 · 2022: $56.27 · 2023: $50.85 · 2024: $102 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $272.07 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $142.30 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $135.86 | 2019-2021 | |
| Amgen INC. | $75.09 | 2019-2020 | |
| Abbott Laboratories | $62.11 | 2022-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $60.39 | 2019 | |
| Amarin Pharma, INC. | $59.40 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.67 | 2019 | |
| Novo Nordisk INC | $53.91 | 2019 | |
| Sanofi Pasteur INC. | $41.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.26 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $30.70 | 2019-2020 | |
| Pfizer INC. | $30.56 | 2019 | |
| Allergan, INC. | $23.73 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $17.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.82 | 2019 | |
| Astellas Pharma US INC | $14.28 | 2023 | Myrbetriq |
| Mission Pharmacal Company | $13.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.